<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865432</url>
  </required_header>
  <id_info>
    <org_study_id>H-41681</org_study_id>
    <nct_id>NCT04865432</nct_id>
  </id_info>
  <brief_title>Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D</brief_title>
  <official_title>Evaluating the Effect of Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D in Vitamin D Deficient/ Insufficient Adults of Various Skin Types: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility interventional study seeking to determine the safety and efficacy of&#xD;
      the Solius Photobiologic System in increasing the serum levels of 25(OH)D in a vitamin D&#xD;
      deficient/insufficient adult population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct an interventional study to determine the changes in the&#xD;
      changes in serum 25-hydroxyvitamin D levels between subjects who receive weekly exposures to&#xD;
      Ultraviolet B Radiation (UVB) generated by the Solius Photobiological System for 4 weeks.&#xD;
      Subjects will first undergo an evaluation of each individual's sensitivity to the Solius&#xD;
      Photobiological System UVB using the device titration system for the first 5 weeks. Once&#xD;
      determined after the 5 weeks, the subjects will be enrolled in a 4-week study where they will&#xD;
      be exposed to their individualized titration evaluation. Approximately 14 adult participants&#xD;
      will be enrolled for serum 25-hydroxyvitamin D screening. The investigators expect to enroll&#xD;
      10 vitamin D-deficient or insufficient subjects in this study. Serum 25-hydroxyvitamin D&#xD;
      levels will be measured prior to the first titration (week 2), prior to the intervention&#xD;
      (week 6) and after the end of the study, and and the changes in serum 25-hydroxyvitamin D&#xD;
      levels will be analyzed. The investigators expect that the levels will increase from the&#xD;
      baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25-hydroxyvitamin D</measure>
    <time_frame>Serum 25-hydroxyvitamin D at 4 weeks of intervention</time_frame>
    <description>Serum 25-hydroxyvitamin D level in at 4 weeks of intervention (the end of study)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Vitamin D Insufficiency</condition>
  <arm_group>
    <arm_group_label>UVB treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 4-week study where they will be exposed to their individualized titration evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVB treatment</intervention_name>
    <description>5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention</description>
    <arm_group_label>UVB treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at least 22 years old&#xD;
&#xD;
          2. Male or Female&#xD;
&#xD;
          3. Skin Type I-VI&#xD;
&#xD;
          4. Women of childbearing potential must be on birth control and not pregnant based on a&#xD;
             negative pregnancy test at baseline.&#xD;
&#xD;
          5. Ability and Willingness to give informed consent and comply to protocol requirements&#xD;
&#xD;
          6. Serum total 25(OH)D &lt; 30 ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing treatment with supplemental or pharmacological doses of vitamin D, vitamin D&#xD;
             metabolites or analogues&#xD;
&#xD;
          2. Pregnant&#xD;
&#xD;
          3. History of underlying photosensitivity&#xD;
&#xD;
          4. Use of medications that cause a photosensitivity reaction (including but not limited&#xD;
             to): tetracycline, tretinoin, amiodarone, doxycycline, naproxen, diphenhydramine,&#xD;
             methotrexate, and hydrochlorothiazide&#xD;
&#xD;
          5. History of skin cancer&#xD;
&#xD;
          6. Plan to received significant sun exposure below the 33rd parallel during study&#xD;
&#xD;
          7. Used tanning or phototherapy devices within the last 30 days&#xD;
&#xD;
          8. Vitamin D supplement use of more than 600 IUs daily.&#xD;
&#xD;
          9. Systemic steroids use&#xD;
&#xD;
         10. H1 antihistamine use in the last 7 days&#xD;
&#xD;
         11. Diagnosed with light allergies (including but not limited to): actinic prurigo,&#xD;
             polymorphous light eruption, or solar urticaria&#xD;
&#xD;
         12. Diagnosed with light sensitivities (including but not limited to): protoporphyria,&#xD;
             photodermatitis, xeroderma pigmentosum, lupus erythematosus, chronic actinic&#xD;
             dermatitis, or UV-sensitive syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Holick, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Holick, PhD MD</last_name>
    <phone>617-358-6139</phone>
    <email>mfholick@bu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arash Shirvani, MD PhD</last_name>
    <phone>617-358-6142</phone>
    <email>hn@bu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Clinical Research Unit (GCRU) BU School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Shirvani, MD PhD</last_name>
      <phone>617-358-6142</phone>
      <email>hn@bu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Ultraviolet B radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

